Premium
Low‐Molecular‐Weight Heparin for the Treatment of Deep Vein Thrombosis
Author(s) -
ThompsonFord Julie K.
Publication year - 1998
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1998.tb03897.x
Subject(s) - heparin , deep vein , low molecular weight heparin , medicine , thrombosis , anticoagulant , bioavailability , surgery , anesthesia , intensive care medicine , pharmacology
Low‐molecular‐weight heparin has been studied for the treatment of deep vein thrombosis in the inpatient setting and more recently in the outpatient setting. It is as safe and effective as unfractionated heparin and is effective when administered subcutaneously once or twice a day. Its bioavailability nears 100% and it has a longer half‐life than unfractionated heparin, resulting in a prolonged anticoagulant effect. A reduction in thrombocytopenia and bleeding complications with low‐molecular‐weight heparin has been reported. Laboratory monitoring is unnecessary. Low‐molecular‐weight heparin provides the opportunity for home therapy.